Oncology On-The-Go Podcast: ASCO 2023 Recap
Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
Nivolumab Combo Yields Sustained Benefit in Advanced Melanoma
Combination therapy with nivolumab and relatlimab produces superior progression-free survival vs nivolumab monotherapy among those with advanced melanoma in the phase 3 RELATIVITY-047 trial.
mRNA Vaccine/Pembrolizumab Reduces Metastasis/Death Risk in Melanoma
mRNA-4157 plus pembrolizumab appears well tolerated without an increase in immune-mediated adverse effects vs pembrolizumab monotherapy among those with high-risk melanoma in the phase 2 KEYNOTE-942 trial.
Dabrafenib Combo Shows Complete Responses in BRAF V600+ Metastatic Melanoma
Targeting apoptosis in BRAF V600-mutated melanoma may be considered for future exploration in the post immunotherapy setting, according to an expert at Moffitt Cancer Center.
Fianlimab/Cemiplimab Yields Activity in Pretreated Metastatic Melanoma
The safety of fianlimab plus cemiplimab appears consistent with the safety profile previously observed with each individual agent among patients with previously treated metastatic melanoma in a phase 1 study.
Sintilimab Combo Reduces Recurrent Disease in Nasopharyngeal Carcinoma
Sintilimab plus chemoradiotherapy produces a higher 3-year distant metastasis-free survival rate vs chemoradiotherapy alone among patients with advanced nasopharyngeal carcinoma in the phase 3 CONTINUUM trial.
LAG-3 Protein/Pembrolizumab Yield Encouraging Responses in Metastatic HNSCC
Treatment with eftilagimod alpha in combination with pembrolizumab appears safe and well tolerated among patients with metastatic head and neck squamous cell carcinoma in the phase 2 TACTI-002 study.
Balstilimab Combo Yields Survival Benefit in Soft Tissue Sarcoma
Most adverse effects in a phase 2 trial related to doxorubicin appear to be expected in the treatment of patients with soft tissue sarcoma.
Darolutamide Shows Potential in Treating AR-Positive Salivary Gland Cancer
With no standard treatment available, darolutamide shows potential activity among patients with androgen receptor–positive salivary gland cancer in the phase 2 DISCOVARY trial.
Cabozantinib Combo Yields Disease Control in Metastatic Soft Tissue Sarcoma
Cabozantinib plus nivolumab and ipilimumab appears to improve progression-free survival vs cabozantinib alone among patients with metastatic soft-tissue sarcoma in a phase 2 trial.
PRT811 Yields Early Anti-Tumor Activity in Uveal Melanoma/Advanced Glioma
Common treatment-emergent adverse effects among patients receiving PRT811 for uveal melanoma or advanced glioma include nausea and vomiting in a phase 1 study.
T-DXd Produces Durable Responses in HER2-Positive Solid Tumors
Trastuzumab deruxtecan may become a new therapy option for patients with HER2-positive tumors, according to an expert from The University of Texas MD Anderson Cancer Center.
Tovorafenib Produces Encouraging Responses in Pediatric Glioma
Treatment with tovorafenib appears well tolerated among pediatric patients with low-grade glioma, according to findings from the phase 2 FIREFLY trial.
Nirogacestat Yields Significant Pain Reduction in Desmoid Tumor Population
Nirogacestat also appears to improve progression-free survival compared with placebo among those with desmoid tumors in the phase 3 DeFi trial.
Vorasidenib Reduces Risk of Progression/Death in Low-Grade Glioma
In the study, 331 patients with IDH-mutated low-grade glioma were randomized to receive oral vorasidenib at 40 mg once daily or matched placebo in 28-day cycles.
Stress Management App Helps to Improve Mental Health in Those With Cancer
Results from the RESTORE study indicate that a cognitive behavioral stress management app improves symptoms of anxiety and depression.
CLDN6 CAR T-cell Therapy Yields Positive Response in Advanced Solid Tumors
Results from a phase 1/2a trial show that efficacy was maintained when BNT211 was used with or without a CLDN6-encoding mRNA vaccine for patients with relapsed/refractory advanced solid tumors.
Expanding Medicaid May Mitigate Disparities in Pancreatic/Gastric Cancers
Medicaid expansion may help overcome inequities in access to care for pancreatic and gastric cancers, with notable benefit in Black patients, according to an expert from The University of Texas MD Anderson Cancer Center.
Minimally Invasive Pancreatectomy Appears Efficacious in Pancreatic Cancer
A positive R0 resection rate helped to confirm the noninferiority of minimally invasive distal pancreatectomy compared with open distal pancreatectomy in those with resectable pancreatic cancer.
Neeraj Agarwal, MD, Discusses Potential Link Between ctDNA, AR Aberrations, and Survival in mCSPC
The appearance of circulating tumor DNA and androgen receptor aberrations yielded lower overall survival rates for patients with metastatic castration-sensitive prostate cancer during the phase 3 TITAN trial, according to Agarwal, MD.
Antonio Calles, MD, Highlights Promising Preliminary Activity of Lurbinectedin and Pembrolizumab in Relapsed SCLC
Early results from the phase 1/2 LUPER study indicated that lurbinectedin in combination with pembrolizumab demonstrated no unexpected toxicities and promising preliminary efficacy in the second line for patients with relapsed small cell lung cancer, according to Antonio Calles, MD.
Melanie Wain Kier, MD, MBA Discusses Socioeconomic Disparities in Supportive Therapies for HR+ Breast Cancer
Income- and race-related disparities concerning supportive therapies for hormone receptor–positive breast cancer require further study to ensure equitable care and access for all patients, according to Melanie Wain Kier, MD, MBA.
Takayuki Yoshino, MD, PhD, Illuminates Research Supporting Panitumumab Over Bevacizumab Plus mFOLFOX6 for Metastatic CRC
Takayuki Yoshino, MD, PhD, spoke about the benefit of panitumumab vs bevacizumab in combination with mFOLFOX6 in the frontline treatment of patients with RAS wild-type metastatic colorectal cancer.
Howard A. Burris, MD, Talks QOL With Durvalumab/Chemo in Advanced Biliary Tract Cancer From TOPAZ-1 Trial
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes data that were presented at 2022 ASCO.
Larotrectinib Trial Yields Promising Real-World Findings in TRK Fusion–Positive Disease
Patients with TRK fusion–positive disease experienced promising survival outcomes following treatment with larotrectinib vs standard of care.
Shubham Pant, MD, Highlights the Potential of ELI-002 2P to Treat MRD in KRAS-Mutant Solid Malignancies
Shubham Pant, MD, spoke to the potential of ELI-002 2P as a treatment for minimal residual disease positivity in patients with KRAS-mutant solid tumors.
Benjamin Cooper, MD, Remarks on Future Analyses of TAK-676 Plus Pembrolizumab in Solid Tumors Undergoing Radiation
Benjamin Cooper, MD, discussed potential future studies exploring TAK-676 plus pembrolizumab after radiation for those with solid tumors.
Long-Term Follow-Up Spotlights Ongoing Positive Outcomes With Selpercatinib in RET Fusion–Positive Cancers
Patients with RET fusion–positive solid tumors continued to experience benefit from treatment with selpercatinib, according to extended follow-up from the phase 1/2 LIBRETTO-001 basket study.
Benjamin Cooper, MD, Examines Rationale Behind Combining TAK-676 With Pembrolizumab After Radiation in Select Solid Tumors
Benjamin Cooper, MD, discussed an ongoing trial examining TAK-676 in combination with pembrolizumab after radiation therapy for patients with non–small cell lung cancer, head and neck cancer, and triple-negative breast cancer.
Frontline Tislelizumab/Chemo Bests Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer
Results of the phase 3 RATIONALE-309 trial demonstrate efficacy of tislelizumab added to chemotherapy for recurrent or metastatic nasopharyngeal carcinoma.
2 Clarke Drive Cranbury, NJ 08512